publication date: Jun. 28, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
Responding to removal of its Medicare “deemed status,” MD Anderson Cancer Center has submitted a “plan of correction” to the Texas Health and Human Services Commission to demonstrate that it is now in compliance with all federal requirements for participation in the Medicare program.
After a 23 year-old patient at MD Anderson Cancer Center died from complications stemming from a platelet transfusion that was contaminated with gram negative coccobacilli, hospital officials are revising internal protocols to demonstrate compliance with federal regulations.
City of Hope is building a $1 billion cancer campus, located on a former air force base in the Great Park neighborhood of Orange County, CA.
- Dinah Singer named NCI deputy director, scientific strategy & development
- Chan Zuckerberg Initiative awards $68M to support the Human Cell Atlas
- UCSF announces precision medicine cancer building
- Laura Mango named medical director, Paul DeJac chief of hospitalist medicine at Roswell Park
The FY19 Defense Appropriation provides $20 million to the Department of Defense Kidney Cancer Research Program to support research of exceptional scientific merit in the area of kidney cancer.
- CheckMate-459 results for Opdivo don’t meet OS endpoint in hepatocellular carcinoma
- Prestige BioPharma report positive top-line phase III results for Tuznue
- Prolaris predicts risk of metastasis in localized prostate cancer
- NCCN releases patient resource for bladder cancer patients
- FDA approves Darzalex + lenalidomide and dexamethasone in multiple myeloma patients ineligible for transplant
- European Commission approves Trecondi for hematopoietic stem cell transplantation
- FDA allows IND application for Athenex PT01
- Intensity Therapeutics, Merck partner to evaluate INT230-6 and Keytruda
- Development collaboration will focus on CAR-T cell therapy for breast cancer
- Integrated Oncology Network acquires e+CancerCare